TG Therapeutics Inc
Company Profile
Business description
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Contact
3020 Carrington Mill Boulevard
Suite 475
MorrisvilleNC27560
USAT: +1 212 554-4484
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
352
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
stocks
Undervalued ASX retailer benefiting from rebound in spending
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,917.50 | 13.80 | -0.15% |
| CAC 40 | 8,068.62 | 17.14 | -0.21% |
| DAX 40 | 24,186.49 | 108.12 | -0.45% |
| Dow JONES (US) | 48,458.05 | 245.96 | -0.51% |
| FTSE 100 | 9,649.03 | 54.13 | -0.56% |
| HKSE | 25,763.85 | 212.94 | -0.82% |
| NASDAQ | 23,195.17 | 398.69 | -1.69% |
| Nikkei 225 | 49,994.30 | 842.25 | -1.66% |
| NZX 50 Index | 13,399.20 | 7.71 | -0.06% |
| S&P 500 | 6,827.41 | 73.59 | -1.07% |
| S&P/ASX 200 | 8,628.60 | 15.30 | -0.18% |
| SSE Composite Index | 3,884.93 | 4.41 | -0.11% |